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Abstract  The  aim  of  this  study  was  to  assess  the  risk  factors  and  clinical  and  microbiological
characteristics  of  community-acquired  pneumonia  (CAP)  in  adult  patients  in  Mexico.  Strepto-
coccus pneumoniae  classiﬁed  as  the  causative  agent  of  CAP  in  adult  patients  and  patients  with
invasive S.  pneumoniae  isolates  presented  to  three  tertiary  teaching  hospitals  during  the  15-
year study  period  were  selected.  Serotyping  and  susceptibility  testing  were  performed  for  all
included isolates.  Clinical  and  demographic  data  were  recorded.  A  total  of  96  patients  infected
with S.  pneumoniae  (71  with  CAP,  25  with  invasive  disease)  were  included.  The  CAP  group
involved more  males  (74.6%)  than  the  invasive  disease  group  (p  =  0.03).  Head  trauma  was  more
common in  the  CAP  group  (21.1%)  than  in  the  invasive  disease  group  (4.0%;  p  =  0.03).  The  most
prevalent serotype  was  19A,  followed  by  serotypes  3  and  23F.  After  the  introduction  of  the
heptavalent  conjugated  pneumococcal  vaccine  (PCV7),  the  prevalence  of  included  serotypes
ch  change  was  found  after  the  introduction  of  the  PCV13  vaccine,
 of  serotype  19A.  Susceptibility  to  all  antimicrobials  tested  except
he  study  period.declined  signiﬁcantly;  no  su
including  in  the  prevalence
vancomycin  declined  over  tPlease  cite  this  article  in  press  as:  Echaniz-Aviles  G,  et  al.  Clinical  and  microbiological  characteristics  of  community-
acquired  pneumonia  associated  with  Streptococcus  pneumoniae  in  adult  patients  in  Mexico.  Rev  Argent  Microbiol.  2018.
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In  conclusion,  head  trauma  was  the  most  common  comorbidity  in  the  CAP  group.  The
most prevalent  serotype  was  19A.  Decreased  susceptibility  to  most  antimicrobials  tested  was
observed.
© 2018  Published  by  Elsevier  Espan˜a,  S.L.U.  on  behalf  of  Asociacio´n  Argentina  de  Microbiolog´ıa.
This is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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Características  clínicas  y  microbiológicas  de  la  neumonía  adquirida  en  la  comunidad
asociada  con  Streptococcus  pneumoniae  en  pacientes  adultos  en  México
Resumen  El  objetivo  de  este  estudio  fue  evaluar  los  factores  de  riesgo  y  las  características
clínicas y  microbiológicas  de  la  neumonía  adquirida  en  la  comunidad  (NAC)  en  pacientes  adultos
en México.  Se  seleccionaron  pacientes  adultos  con  NAC  con  Streptococcus  pneumoniae  como
agente causal  y  pacientes  con  aislamientos  invasivos  de  S.  pneumoniae  que  concurrieron  a  tres
hospitales  de  ensen˜anza  de  tercer  nivel  durante  el  período  de  estudio  de  15  an˜os  (2000-2015).
Se realizaron  pruebas  de  serotipiﬁcación  y  sensibilidad  con  todos  los  aislados  incluidos.  Se
colectaron los  datos  clínicos  y  demográﬁcos.  Se  incluyeron  en  total  96  pacientes  infectados  con
S. pneumoniae  (71  con  NAC  y  25  con  enfermedad  invasiva).  El  grupo  con  NAC  incluía  más  varones
(74,6%) que  el  grupo  de  enfermedad  invasiva  (p  =  0,03).  El  traumatismo  craneoencefálico  fue
más frecuente  en  el  grupo  NAC  (21,1%)  que  en  el  grupo  con  enfermedad  invasiva  (4,0%;  p  =  0,03).
El serotipo  más  frecuente  fue  19A,  seguido  de  los  serotipos  3  y  23F.  Después  de  la  introducción
de la  vacuna  antineumocócica  conjugada  heptavalente  (PCV7),  la  prevalencia  de  los  serotipos
incluidos  en  aquella  disminuyó  signiﬁcativamente;  no  sucedió  lo  mismo  después  de  la  intro-
ducción de  la  PCV13,  incluso  en  relación  con  la  prevalencia  del  serotipo  19A.  La  sensibilidad  a
todos los  antimicrobianos  evaluados,  excepto  la  vancomicina,  disminuyó  durante  el  período  de
estudio.
En conclusión,  el  traumatismo  craneoencefálico  fue  la  comorbilidad  más  frecuente  en  el  grupo
con NAC.  El  serotipo  más  frecuente  fue  el  19A,  y  se  observó  disminución  de  la  sensibilidad  a  la
mayoría de  los  antimicrobianos  probados  a  lo  largo  del  período  considerado.
© 2018  Publicado  por  Elsevier  Espan˜a,  S.L.U.  en  nombre  de  Asociacio´n  Argentina  de  Microbi-
olog´ıa. Este  es  un  art´ıculo  Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
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treptococcus  pneumoniae  is  among  the  most  frequently
solated  pathogens  in  a  variety  of  infections,  including  inva-
ive  infections  such  as  bacterial  meningitis  and  non-invasive
nfections  such  as  community-acquired  pneumonia  (CAP)12
nd  otitis  media10.  Thus,  vaccination  to  prevent  diseases
ssociated  with  this  microorganism  remains  one  of  the  most
mportant  goals  of  public  health.
CAP  is  among  the  most  common  infectious  diseases  and
 signiﬁcant  cause  of  mortality  and  morbidity  worldwide.
istinctive  bacterial  pathogens  that  cause  CAP  include  S.
neumoniae,  and  Haemophilus  inﬂuenzae; the  ﬁrst  species
eing  a  leading  causative  agent9,17
As  a  consequence  of  extensive  antibiotic  use,  the  inci-
ence  of  S.  pneumoniae  drug  resistance  has  increased
larmingly;  up  to  30%  of  S.  pneumoniae  strains  worldwide
re  now  considered  to  be  multidrug-resistant11,12.  Thus,
urveillance  of  the  drug  resistance  of  this  microorganism  in
15Please  cite  this  article  in  press  as:  Echaniz-Aviles  G,  et  al.  C
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arious  populations  and  age  groups  is  important .
In  2006,  the  ﬁrst  vaccine  for  the  prevention  of  infections
ssociated  with  S.  pneumoniae  in  children  was  introduced  in
exico.  The  heptavalent  conjugated  pneumococcal  vaccine
i
S
sPCV7)  included  seven  serotypes  (4,  6B,  9V,  14,  18C,  19F,  and
3F)  and  was  distributed  in  lower-income  municipalities.  It
as  incorporated  into  the  Mexican  universal  immunization
rogram  in  200815 and  was  replaced  in  2011  by  PCV13,  which
dditionally  includes  serotypes  1,  3,  5,  6A,  7F,  and  19A  in  a
 +  1  schedule6,14.
For  the  prevention  of  disease  in  adults  aged  ≥65  years,
he  pneumococcal  polysaccharide  vaccine  (PPSV  23)  is
ecommended  as  part  of  the  Mexican  universal  immuniza-
ion  program  since  1983.  This  vaccine  protects  against  23
erotypes  (1,  2,  3,  4,  5,  6B,  7F,  8,  9N,  9V,  10A,  11A,  12F,  14,
5B,  17F,  18C,  19A,  19F,  20,  22F,  23F  and  33F).
Epidemiological  surveillance  of  pathogens  associated
ith  vaccine-preventable  diseases  in  speciﬁc  populations
nd  age  groups  is  relevant  to  detect  changes  in  epidemiology
ver  time  and  to  guide  public  health  policy  and  the  develop-
ent  of  control  strategies5.  Vaccine  coverage  for  a  targeted
dult  population  is  based  on  surveys5. Information  about
irculating  S.  pneumoniae  serotypes  in  adult  patients  in  Mex-
co  with  CAP  and  the  drug  susceptibility  of  these  serotypeslinical  and  microbiological  characteristics  of  community-
e  in  adult  patients  in  Mexico.  Rev  Argent  Microbiol.  2018.
s  scarce,  as  the  Sistema  Regional  de  Vacunas  Laboratory
urveillance  Program  initially  focused  on  children  with  inva-
ive  pneumococcal  infections8. Thus,  there  remains  a  huge
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Table  1  Demographic  and  clinical  characteristics  of  patients  with  pneumococcal  diseases  in  Mexico
Characteristic  Total
n  =  96
CAP  (LRT
Non-invasive-
isolates)
n  =  66
Invasive
isolates
n  =  25
p
Male,  n  (%)  66  (68.7)  53  (74.6)  13  (52.0)  0.03
Median age  y  (range)  43  (94--14)  42  (94--14)  48  (80--16)  0.13
LOS (days)  (mean  ±  SD)  10  (115--0)  11  (115--0)  8  (52--0)  0.32
28-Day mortality,  n  (%)  14  (14.58)  8  (11.26)  6  (24)  0.12
Primarily medical  diagnosis,  n  (%)  65  (66.6)  44(61.9)  20  (80.0)  0.16
Comorbidities
Diabetes, n  (%)  11  (15.5)  9  (12.6)  2  (8.0)  0.72
HIV/AIDS, n  (%)  4  (4.1)  3  (4.2)  1  (4.0)  0.96
Cancer, n  (%)  8  (8.3)  5  (7.0)  3  (12.0)  0.72
Head trauma,  n  (%)  16  (16.6)  15  (21.1)  1  (4.0)  0.03
Renal insufﬁciency,  n  (%)  3  (3.1)  3  (4.2)  NA
Pregnancy,  n  (%)  2  (2.0)  1  (1.4)  1  (4.0)  0.45
Laboratory results  (mean  ±  SD)
Hemoglobin  (g/dl)  12.12  (19.3--7.5)  11.9  (18--7.5)  12.8  (19.3--7.8)  0.21
Leucocytes (mil/mm3)  12.64  (37--2.4)  11.8  (34.8--2.4)  15.17  (37--2.56)  0.16
Platelets (mil/mm3)  260.4  (1069--37.1)  256.41  (1069--37.1)  245.6  (364--103)  0.66
Albumin g/dl  3.12  (4.9--1)  3.13  (4.9--1.1)  3.07  (4.5--1)  0.90
Creatinine (mg/dl)  1.52  (32--0.4)  1.64  (32--0.4)  1.18  (3.3--0.4)  0.91
LOS, length of stay; HIV/AIDS, human immunodeﬁciency virus infection/acquired immunodeﬁciency syndrome. LRT: Lower respiratory
tract.
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rneed  to  describe  the  clinical  and  microbiological  charac-
teristics  of  CAP  in  adult  patients  in  Mexico.  This  need  is
supported  by  the  Mexican  data  requirement  for  the  autho-
rized  introduction  of  PCV13  for  adults.  The  aim  of  this  study
was  to  assess  the  risk  factors,  microbiology,  and  antibiotic
resistance  of  CAP  in  adult  patients  in  Mexico.
Methods
Design,  setting,  and  patients
Data  and  samples  from  patients  who  presented  to  three
tertiary  care  hospitals  over  a  15-year  period  (January
2000--September  2015)  were  included  in  this  study.  The  insti-
tutions  were  the  Hospital  Universitario  Dr.  José  Eleuterio
González,  a  500-bed  public  hospital  in  the  city  of  Monter-
rey;  the  Hospital  San  José,  Tec  de  Monterrey,  a  220-bed
private  hospital;  and  the  Hospital  Civil  Fray  Antonio  Alcalde
de  Guadalajara,  a  1000-bed  public  hospital.
Cases  with  clinical  and  radiological  evidence  of  CAP
were  detected  through  a  retrospective  review  of  all  respira-
tory  samples  received  from  the  microbiology  laboratory  of
each  hospital.  Inclusion  criteria  were  age  ≥18  years,  lower
respiratory  tract  (LRT)  sample  obtained  within  48  h  of  hospi-Please  cite  this  article  in  press  as:  Echaniz-Aviles  G,  et  al.  C
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tal  admission,  radiographic  evidence  of  new  inﬁltrate,  and
three  or  more  of  the  following  symptoms:  dyspnea,  hemopt-
ysis,  cough,  sputum  production,  chest  pain,  fever,  headache,
and  abnormalities  on  chest  auscultation  or  percussion.
l
t
vOnly  patients  with  radiological  changes  consistent  with
neumonia  radiology  reports  were  included.  Clinical  data,
ncluding  outcomes,  comorbidities,  and  antibiotic  prescrip-
ions,  were  recovered  retrospectively  from  the  patients’
ospital  records.
Patients  with  at  least  one  positive  S.  pneumoniae  culture
nd  a  clinical  diagnosis  of  pneumonia  were  included.  We  also
ncluded  patients  with  invasive  disease  for  the  comparison
f  clinical  and  microbiological  data.
Clinically  relevant  non-invasive  CAP  isolates  were  deﬁned
s  those  from  sputum,  transtracheal  aspiration,  or  bron-
hoalveolar  lavage  and  others  in  which  S.  pneumoniae  grew
s  a  single  or  predominant  colony.  Sputum  samples  with
25  leukocytes  and  <10  epithelial  cells  per  low-power  ﬁeld
ere  processed.  The  clinical  diagnosis  of  pneumonia  was
ased  on  (a)  positive  S.  pneumoniae  culture,  (b)  posi-
ive  radiographic  ﬁndings,  (c)  and  clinical  data  indicating
neumonia.  Invasive  isolates  were  isolated  from  blood,  cere-
rospinal  ﬂuid,  pleural  ﬂuid,  and  ascites.  Specimens  were
rocessed  according  to  the  guidelines  described  in  the  Clin-
cal  Microbiology  Procedures  Handbook.
Patients  for  whom  clinical  information  was  available
ere  included.  Sex,  age,  length  of  hospital  stay,  and  over-
ll  mortality  rate,  as  well  as  comorbidities  and  laboratory
esults,  were  analyzed.  Two  different  periods  were  ana-
yzed:  the  pre-PCV7  period  considered  from  the  year  2000
o  2007  and  the  post-PCV7--PCV13  period  from  2008  to  2015.linical  and  microbiological  characteristics  of  community-
e  in  adult  patients  in  Mexico.  Rev  Argent  Microbiol.  2018.
This  work  was  approved  by  the  Ethical  Committee  of  Uni-
ersidad  de  Guadalajara.
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Table  2  Distribution  of  pneumococcal  serotypes  isolated  from  adult  patients  according  to  the  prePCV7  and  postPCV7-PCV13
period.
Serotypes  Vaccine  period  p
Pre-PCV7  Post-PCV7--PCV13
(n =  18)  (n  =  78)
n  (%)  n  (%)
PCV7
4  1  (5.55)  0  0.18
6B 2  (11.11)  2  (2.56)  0.15
9V 1  (5.55) 1  (1.28) 0.34
14 1  (5.55) 0  0.18
19F 2  (11.11) 3  (3.84) 0.23
23F 3  (16.66)  4  (5.12)  0.11
Total 10  (55.5)  10  (12.8)  0.0003
PCV 13
3  2  (11.11) 9  (11.53)  1.00
6A 0  3  (3.84) 1.00
19A 2  (11.11) 17  (21.79)  0.51
Total 4 (22.22) 29  (37.16) 0.28
PPSV23
11A 1  (5.55)  3  (3.84)  0.57
15B 0  5  (6.4)  1.00
Others 3  (16.66)  20  (25.6)  0.16
Total 4  (22.22)  28  (35.8)  0.25
Non-vaccine
6C 0  1  (1.28)  1.00
15A, 15C  0  4  (5.12)  1.00
23A 0  4  (5.12)  1.00
35B 0  1  (1.28)  1.00
38 0  1  (1.28)  1.00
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(Total 0  
Serotypes 8C (PCV7); 1, 5, and 7F (PCV10 and 13); and 10A and 22
icrobiological  and  susceptibility  testing
.  pneumoniae  isolates  were  identiﬁed  by  standard  proce-
ures  and  characteristics,  including  Gram  staining,  negative
atalase  results,  sensitivity  to  optochin,  and  bile  solubil-
ty  testing.  Serotyping  was  performed  using  the  Quellung
eaction  and  serum  from  the  Statens  Serum  Institut  (Copen-
agen,  Denmark).
Susceptibility  testing  was  performed  by  broth  microdi-
ution  following  the  guidelines  of  the  Clinical  and
aboratory  Standards  Institute3.  Susceptibility  to  penicillin,
rythromycin,  chloramphenicol,  cefotaxime,  trimetho-
rim/sulfamethoxazole,  and  vancomycin  was  tested.
.  pneumoniae  ATCC  4919  was  used  as  a  control  strain.
tatistical  analysis
e  used  conventional  dispersion  methods  for  descriptionPlease  cite  this  article  in  press  as:  Echaniz-Aviles  G,  et  al.  C
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nd  non-parametric  tests  for  comparison  of  the  data.  The
hi-squared  test  was  used  to  compare  dichotomous  varia-
les,  and  the  Wilcoxon  rank-sum  test  was  used  for  linear
ariables.  p  values  ≤0.05  were  considered  to  be  signiﬁcant.
f
(
w
a11  (14.10)  0.11
SV23) were not detected.
nalyses  were  conducted  using  SPSS  software  (version  18;
PSS  Inc.,  Chicago,  IL,  USA).
esults
solates,  study  population,  and  clinical  data
 total  of  96  S.  pneumoniae  isolates  with  the  patients’
linical  information  were  included  in  the  study.  Sites  of
solation  were  non-invasive  LRT  secretions  (CAP;  n  =  66);
ther  non-invasive  clinical  samples  (n  =  5)  and  invasive  spec-
mens  (n  =  25):  blood  (n  =  12),  cerebrospinal  ﬂuid  (n  = 6),
scites  (n  =  1),  pleural  ﬂuid  (n  =  5),  and  brain  abscess  (n  =  1).
he  CAP  group  included  more  men  (74.6%)  than  the  invasive
roup  (52%).  The  median  patient  age  was  43  years  (range,
8--94  years),  and  66  (68.7%)  patients  were  male.
The  length  of  hospital  stay  ranged  from  0  to  115  days
median,  10  days;  Table  1).  Head  trauma  was  the  mostlinical  and  microbiological  characteristics  of  community-
e  in  adult  patients  in  Mexico.  Rev  Argent  Microbiol.  2018.
requent  comorbidity  in  patients  with  LRT  S.  pneumoniae
21.12%),  and  neoplasms  were  most  frequent  in  patients
ith  invasive  strains  (12%).  Demographic  and  clinical  char-
cteristics  are  shown  in  Table  1.
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Table  3  Distribution  of  pneumococcal  serotypes  isolated  from  invasive  and  non-invasive  diseases  by  vaccine  period  in  adult
population in  Mexico
Pneumococcal  serotypes  Total  Pre-PCV7
n  =  18
Post-
PVC7/PCV13
n  =  78
p
Invasive
diseases
n
Non-invasive
diseases
n
Invasive
diseases
n
Non-invasive
diseases
n
4  1  1  0.19
6A 3  3  1.00
6B 4  1  1  2  0.15
9V 2  1  1  0.34
14 1  1  0.18
19F 5  2  3  0.23
23F 7  1  2  1  3  0.11
3 11  1  1  4  5  1.00
19A 19  1  1  5  12  0.34
20 2  1  1  0.34
11A 4  1  3  0.57
13 2  2  1.00
38 1  1  1.00
15A 4  1  2  1  0.57
15B 5  1  4  0.57
15C 2  1  1  1.00
16F 1  1  1.00
17F 2  2  1.00
18A 1  1  1.00
23A 4  4  1.00
23B 3  3  1.00
24F 1  1  1.00
28A 2  1  1  1.00
6C 1  1  1.00
7C 2  2  1.00
9N 1  1  0.19
35B 1  1  1.00
N/T 4  1  3  1.00
Total 96  4  (22.2%)  14  (77.7%)  20  (25.6%)  58  (74.3%)
en pr
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n
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T
sN/T = non-typable.
Value p = signiﬁcance of pneumococcal disease by serotype betwe
Serotypes  and  drug  susceptibility
All  pneumococcal  isolates  were  serotyped  with  twenty-nine
serotypes  identiﬁed;  4  strains  were  considered  non-typable.
Serotype  19A  was  the  most  common  serotype  (19/19.8%),
followed  by  serotypes  3  (11/11.4%)  and  23F  (7/7.3%).
We  detected  serotypes  included  in  any  of  the  four  avail-
able  vaccines  (3,  4,  6B,  9V,  14,  19F,  23F,  19A,  9N,  11A,
15B,  17F,  20,  22F,  and  35B)  and  13  serotypes  not  included
in  any  currently  available  vaccine  (6C,  7C,  13,  15,  15A,  18A,
15C,  16F,  23A,  23B,  24F,  28A,  and  38).  We  also  detected
serotype  6A,  which  is  included  in  PCV13  but  not  in  the
polyvalent  PPSV23  recommended  for  the  adult  population
(Table  2).  Serotypes  1,  5,  7F,  2,  8,  10A,  12F,  and  18C,  whichPlease  cite  this  article  in  press  as:  Echaniz-Aviles  G,  et  al.  C
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are  included  in  any  of  the  PCV7,  PCV10,  PCV13,  or  PPSV23
vaccines,  were  not  detected.
When  examined  by  the  pre-  and  post  PCV7  periods,  we
found  18  pneumococcal  isolates  in  the  pre-PCV7  and  78
i
t
Fe-PCV7 and post-PCV7/PCV13 period.
n  the  post-PCV7--PCV13  period.  The  circulation  of  PCV7
erotypes  declined  after  2008  (p  <  0.0003),  whereas  no
eduction  was  observed  for  the  PCV13  serotypes.  A  slight  but
on-signiﬁcant  increase  in  the  circulation  of  serotype  19A  in
he  post-PCV  period  was  detected  (Table  2).  There  were  4
22.2%)  invasive  pneumococcal  infections  in  the  pre-PCV7
eriod  and  20  (25.6%)  in  the  post-PCV7-PCV13  period  com-
ared  to  14  (77.7%)  and  58  (74.3%)  non-invasive  infections,
espectively,  as  shown  in  Table  3. Isolates  not  included  in
ny  vaccine  were  only  found  in  the  post-PCV7-PCV13  period.
o  signiﬁcant  differences  were  found  between  serotypes
ausing  invasive  and  non-invasive  diseases  as  shown  in
able  3,  with  serotypes  3  and  19A  as  the  most  frequent
erotypes  in  both  infections.linical  and  microbiological  characteristics  of  community-
e  in  adult  patients  in  Mexico.  Rev  Argent  Microbiol.  2018.
There  were  6  pneumococcal  meningitis  cases  reported
n  the  post  PCV7  period,  and  3  of  them  showed  resistance
o  penicillin.  All  of  them  were  susceptible  to  cefotaxime.
or  non-meningitis  isolates,  an  important  reduction  in
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Table  4  Drug  susceptibility  of  S.  pneumoniae  throughout  the  study  period.
Vaccine  period  PEN
meningitis
(n  =  6)
PEN  Non-
meningitis
(n  =  90)
CTX
meningitis
(n  =  6)
CTX  Non-
meningitis
(n  =  90)
ERY  (n  =  96)  CHL  (n  =  96)  TMP/SMX
(n  =  96)
Pre-PCV7  (n  =  18)
S,  n  (%)  0  (0)  15  (16.6)  0  (0)  15  (16.6)  14  (14.6)  17  (17.7)  7  (7.3)
I, n  (%)  0  (0)  1  (1.1)  0  (0)  1  (1.1)  0  (0)  0  (0)  0  (0)
Resistant, n  (%)  0  (0)  2  (2.2)  0  (0)  2  (2.2)  4  (4.2)  1  (1.0)  11  (11.5)
Post-PCV7 (n  =  78)
S,  n  (%)  3  (50.0)  43  (4.5)  6  (100)  41  (45.5)  49  (51.0)  58  (60.4)  19  (19.8)
I, n  (%) 0  (0)  20  (22.2)  0  (0)  18  (20.0)  0  (0)  0  (0)  15  (15.6)
R, n  (%) 3  (50.0) 9  (10.0) 0  (0) 13  (14.4)  29  (30.2)  20  (20.8)  44  (45.8)
p 1.00  0.16  1.00  0.09  0.28  0.10  0.24
The following breakpoints were used for the interpretation of penicillin susceptibility. For non-meningeal cases: S: susceptible, S,
≤2 mg/l; I, 4 mg/l; and R, ≥8 mg/l. For meningeal cases: S, ≤0.06 mg/l, and R, ≥0.12 mg/l. The following breakpoints were used for
cefotaxime. For non-meningeal cases: S, ≤1 mg/l; I, 2 mg/l; and R, ≥4 mg/l. For meningeal cases: S, ≤0.5 mg/l; I, 1 mg/l; and R,
≥2 mg/l.
S: susceptible, I: intermediate; R: resistant; PEN: Penicillin; CTX: cefotaxime; ERY: erythromycin; CHL: chloramphenicol; TMP/SXT,
trimethoprim/sulfamethoxazole. All isolates were susceptible to vancomycin.
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LValue p represents signiﬁcance in decreased susceptibility.
usceptibility  to  all  antimicrobials  except  vancomycin  (100%
n  all  isolates)  during  the  study  period  was  observed
Table  4),  particularly  for  erythromycin  and  TMP/SMX.  Most
f  the  increase  in  antimicrobial  resistance  was  due  to
erotype  19A  in  the  post-PCV7-PCV13  period  (data  not
hown).
iscussion
n  this  study,  we  aimed  to  assess  the  risk  factors  and  micro-
iological  characteristics  of  CAP  in  adult  patients  from  three
ertiary  teaching  hospitals  in  Mexico  over  a  period  of  15
ears.  The  most  frequent  comorbidity  in  patients  with  CAP
.  pneumoniae  was  head  trauma.  This  association  is  difﬁ-
ult  to  explain,  as  head  trauma  is  viewed  as  a  risk  factor
or  infection  with  invasive  isolates,  rather  than  CAP  iso-
ates.  The  most  frequent  comorbidities  in  patients  with
on-respiratory  strains  were  neoplasms,  which  is  not  sur-
rising  because  invasive  disease  (septicemia)  caused  by
.  pneumoniae  is  a  common  complication  of  cancer.
Invasive  pneumococcal  disease  is  common  in  Latin
merica2,4,16,  and  the  effectiveness  of  PPSV23  in  adult
atients  varies  signiﬁcantly.  Thus,  adequate  information
bout  circulating  serotypes  is  crucial  to  deﬁne  vaccination
trategies  and  aid  vaccine  development.  In  this  study,  we
nalyzed  S.  pneumoniae  serotype  frequencies  according  to
accine  periods.  The  changes  detected  before  and  after
CV7  and  PCV13  were  smaller  in  these  adults  than  in  those
eported  for  children,  in  whom  increases  in  serotypes  19A
nd  7C  and  a  dramatic  reduction  in  serotype  19A  after  the
ntroduction  of  PCV13  have  been  detected7.Please  cite  this  article  in  press  as:  Echaniz-Aviles  G,  et  al.  C
acquired  pneumonia  associated  with  Streptococcus  pneumonia
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Theoretical  serotype  vaccine  coverage  for  the  pre-PCV7
nd  the  post-PCV7--PCV13  periods  were  55.5%  and  12.8%  for
CV7;  77.8%  and  34.6%  for  PCV13  and  94.4%  and  60.3%  for
PS23  respectively.
t
w
(
sThe  most  prevalent  serotype  in  this  study  during  the
eriod  before  the  introduction  of  PCV7  was  23F,  followed
y  serotypes  6B,  19A,  and  19F.  After  the  introduction  of
CV7,  the  frequencies  of  serotypes  23F  and  6B  decreased,
nd  serotypes  19A  and  15B  predominated.  With  the  introduc-
ion  of  PVC13,  serotype  19A  continued  to  be  predominant,
ollowed  by  serotypes  3  and  23A.  Although  the  prevalence
f  serotype  19A  declined  after  the  introduction  of  PCV13
n  children,  no  such  effect  was  observed  in  the  adults  in
his  study;  on  the  contrary,  the  frequency  of  this  serotype
ncreased  slightly.
Even  with  the  recent  changes  in  dosing  regimens  for
CV10,  an  epidemiological  impact  is  apparent  in  adults,
ith  a  reduction  in  PCV7  serotypes  after  2008.  In  the  cur-
ent  study,  we  detected  no  reduction  in  PCV13  or  PPSV23
erotypes.  This  ﬁnding  has  also  been  reported  for  the
apanese  population15.
After  the  introduction  of  PCV7  for  children  under  2
ears,  there  has  been  a  decrease  in  the  transmission  of
he  included  serotypes  to  adults.  This  could  be  due  to
 herd  effect  but  cannot  be  concluded  with  certainty.
erotypes  3  and  19A  have  low  immunogenicity  (PCV13),
o  they  do  not  manage  to  generate  a  decrease  in  colo-
ization  of  vaccinated  children,  so  they  continue  to  be
ransmitted  to  adults.  It  underscores  the  need  for  surveil-
ance  of  speciﬁc  populations,  particularly  adults  (including
hose  with  CAP),  because  this  population  may  be  a  reservoir
or  different  serotypes  and  the  effects  seen  in  children  do
ot  reﬂect  protection  of  older  and  susceptible  community
embers.
In  one  of  the  largest  and  most  recent  studies  of  the
ntimicrobial  susceptibility  of  S.  pneumoniae  conducted  in
atin  America12,  182  S.  pneumoniae  isolates  were  foundlinical  and  microbiological  characteristics  of  community-
e  in  adult  patients  in  Mexico.  Rev  Argent  Microbiol.  2018.
o  be  predominantly  non-susceptible  to  penicillin  (51.6%),
ith  the  highest  rates  of  resistance  observed  in  Mexico
84.8%)  and  Venezuela  (81.2%).  Similarly,  elevated  non-
usceptibility  rates  for  ceftriaxone  were  detected  in  both
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Streptococcus  pneumoniae  in  Mexican  adults  
countries  (21.1--43.7%)12.  We  identiﬁed  a  notable  increase
in  non-susceptibility  to  penicillin  in  our  isolates  and  a  steady
decrease  in  susceptibility  to  cephalosporins;  both  changes
are  much  greater  than  previously  reported8.
For  community  meningitis  in  our  population,  cefotaxime
or  ceftriaxone  plus  vancomycin  are  used.  For  NAC,  lev-
oﬂoxacin  or  ceftriaxone  plus  a  macrolide  are  used.  If  there
is  suspicion  of  penicillin-resistant  S.  pneumoniae, then  van-
comycin  is  added.
Lower  susceptibility  to  trimethoprim/sulfamethoxazole
and  similar  susceptibility  to  erythromycin  have  been  found
in  isolates  collected  from  children1.
This  study  has  several  limitations.  As  we  were  not  able
to  document  the  patients’  immunization  status,  the  inﬂu-
ence  of  vaccination  on  the  selection  of  individual  serotypes
remains  unclear.  In  addition,  we  included  sputum  sam-
ples,  which  are  practical,  but  imperfect,  specimens  for  the
microbiological  investigation  of  CAP.  Microscopic  examina-
tion  of  sputum  quality  was  performed  for  all  samples,  and
only  mucopurulent  material  was  tested.  Nevertheless,  spu-
tum  is  always  at  risk  of  contamination  with  oropharyngeal
microbiota.  Despite  these  limitations,  national  guidelines
recommend  sputum  investigation  for  patients  admitted  to
hospital  with  moderate  to  severe  CAP,  to  aid  microbiological
diagnosis13.
In  this  study,  more  patients  with  CAP  than  with  invasive
disease  were  male,  and  head  trauma  was  the  most  common
comorbidity  in  the  CAP  group.  The  most  prevalent  serotype
was  19A,  and  the  proportion  of  PCV7  serotypes  declined
after  2008;  no  reduction  in  PCV13  serotypes  was  observed.
Decreased  susceptibility  to  most  antimicrobials  tested  was
observed.  Our  results  underscore  the  need  for  surveillance
of  the  adult  population  to  aid  in  the  control  of  diseases
associated  with  S.  pneumoniae.
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